Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity

Journal of Toxicology and Environmental Health - Part B: Critical Reviews

Volumn 12, Issue 5-6, 2009, Pages 334-361

  Neafsey, Patricia ^a   Ginsberg, Gary ^b   Hattis, Dale ^c   Sonawane, Babasaheb ^d  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b CDC   (United States)

^c CLARK UNIVERSITY   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMITRIPTYLINE; CARCINOGEN; CHLORPYRIFOS; CYTOCHROME P450 2D6; DEBRISOQUINE; DIMPYLATE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; NORTRIPTYLINE; PARACETAMOL; PARATHION; XENOBIOTIC AGENT;

BLADDER CANCER; BREAST CANCER; CANCER RISK; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME METABOLISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LARYNX CANCER; LUNG CANCER; MONTE CARLO METHOD; PARKINSON DISEASE; PHENOTYPE; POPULATION DISTRIBUTION; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; TOXICOKINETICS;

CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP2D6; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENETICS, POPULATION; HUMANS; MOLECULAR EPIDEMIOLOGY; MONTE CARLO METHOD; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 75749116800     PISSN: 10937404     EISSN: 15216950     Source Type: Journal    
DOI: 10.1080/10937400903158342     Document Type: Review

References (156)

1. Agundez J., Ledesma, M., and Ladero, J. 1995. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 57:265-269.
2. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodriguez, F., and Ingelman-Sundberg, I. 1996. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278:441-446.
3. Alcorn, J., and McNamara, PJ. 2002. Ontogeny of hepatic and renal systemic clearance pathways in infants. Clin. Pharmacokinet. 41:959-998. (Pubitemid 35168438)
4. Allorge, D., Breant, D., Harlow, J., Chowdry, J., Lo-Guidice, JM., Chevalier, D., Cauffiez, C., Lhermitte, M., Blaney, F. E., Tucker, G. T., Broly, F., and Ellis, S. W. 2005. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440his substitution. Proteins 59:339-346.
5. Antonarakis, S. E. 1998. Recommendations for a nomenclature system for human gene mutations. Nomenclature working group. Hum. Mutat. 11:1-3.
6. Anwar, W., Abdel-Rahman, S., El Zein, R., Mostafa, H., and Au, W. 1996. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 17:1923-1929.
7. Ayesh, R., Idle, J., Ritchie, J. C., Crothers, M. J., and Hetzel, M. 1984. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169-170.
8. Aynacioglu, AS., Sachse, C., Bozkurt, A., Kortunay, S., Nacak, M., Schroder, T., Kayaalp, SO., Roots, I., and Brockmoller, J. 1999. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol.Ther. 66:185-192.
9. Bear, W. L., and Teel, R. W. 2000. Effects of citrus phytochemicals on liver and lung cytochrome P450 activity and on the in vitro metabolism of the tobacco-specific nitrosamine NNK. Anticancer Res. 20:3323-12229
10. Benhamou, S., Bouchardy, C., and Dayer, P. 1996. Effects of CYP2D6 activity and tobacco on larynx cancer risk. Cancer Epidemiol. Biomarkers Prev. 5:683-686. (Pubitemid 26304641)
11. Bernal., ML., Sinues, B., Johansson, I., McLellan, RA., Wennerholm, A., Dahl, M., Ingelman-Sundberg, M., and Bertilsson, L. 1999. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 9:657-660.
12. Bertilsson L., Lou, Y., Du, Y., Liu, Y., Kuang, T., Liao, X., Wany, K., Reviriego, J., Iselius, L., and Sjoqvist, F. 1992. Pronounced differences between native Chinese and Swedish populations in the polymorphis hydroxylations of debrisoquin and s-mephenytoin. Clin. Pharmacol.Ther. 51:388-397.
13. Bertz, R. J., and Granneman, G. R. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:210-258.
14. Bogni, A., Monshouwer, M., Moscone, A., Hidestrand, M., Ingelman-Sundberg, M., Hartung, T., and Coecke, S. 2005. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol. In Vitro 19:621-629. (Pubitemid 40719537)
15. Bosch, T. M., Doodeman, V. D., Smits, P. H., Meijerman, I., Schellens, J. H., and Beijnen, J. H. 2006. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol. Diagn. Ther. 10:175-185.
16. Bouchardy, C., Benhamou, S., and Dayer, P. 1996. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res. 56:251-253. (Pubitemid 26026349)
17. Bouchardy, C., Benhamou, S., Jourenkova, N., Dayer, P., and Hirvoven, A. 2001. Metabolic genetic polymorphisms and susceptibility to lung cancer. Lung Cancer 32:109-112.
18. Boyer, E. W., Quang, L., Woolf, A., and Shannon, M. 2001. Dextromethorphan and ecstasy pills. J. Am. Med. Assoc. 285:409-410.
19. Branch, R., Chern, H., Adedoyin, A., Romkes-Sparks, M., Lesnick, T., Persad, R., Wilkinson, G., Fleming, C., Dickinson, A., and Sibley, G. 1995. The procarcinogen hypothesis for bladder cancer: Activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 5:S97-S102.
20. Brockmoller, J., Cascorbi, I., Kerb, R., and Roots, I. 1996. Combined analysis of inherited polymorphisms in arlyamine N-acetyltransferase 2, glutathione S-transferases M1 and TI, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56:3915-3925.
21. Butler, A. M. and Murray, M. 1997. Biotransformation of parathion in human liver: Participation of CYP3A4 and its inactivation during microsomal parathion activation. J. Pharmacol. Exp. Ther. 280:966-973.
22. Caccia, S. 2000. Biotransformation of post-clozapine antipsychotics. Clin. Pharmacokinet. 38:393-414.
23. Cai, W. M., Nikoloff, D. M., Pan, R. M., de Leon, J., Fanti, P., Fairchild, M., Koch, W. H., and Wedlund, P. J. 2006. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: Implications for clinical practice and genetic testing. Pharmacogenom. J. 6:343-350.
24. Caporaso, N., Hayes, RB., Dosemeci, M., Hoover, R., Ayesh, R., Hetzel, M., and Idle, J. 1989. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 49:3675-3679.
25. Caporaso, N. E., Tucker, M. A., and Hoover, R. N. 1990. Lung cancer and the debrisoquine metabolic phenotype. JNCI 82:1264-1272.
26. Cascorbi, I. 2003. Pharmacogenetics of cytochrome p4502D6: Genetic background and clinical implication. Eur. J. Clin. Invest. 33:17-22.
27. Cho, H. Y., and Lee, Y. B. 2006. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch. Pharm. Res. 29:525-533.
28. Christensen, P. M., Gotzsche, P. C., and Brosen, K. 1997. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta-analysis. Eur. J. Clin. Pharmacol. 51:389-393.
29. Christensen, P. M., Gotzsche, P. C., and Brosen, K. 1998. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: A meta-analysis. Pharmacogenetics 8:473-479.
30. Coleman, T., Ellis, S., Martin, I., Lennard, M., and Tucker, G. 1996. 1-Methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4-Implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 277:685-690.
31. Crespi, C. L., Penman, B. W., Gelboin, H. V., and Gonzalez, F. S. 1991. A tobacco smoke-derived nitrosamine, 4-(methlynitrosamino)-1-(3-pyridyl)-1- butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P450 2D6. Carcinogenesis 12:1197-1201.
32. Dahl, M., Johansson, I., Bertilsson, L., Ingelman-Sunberg, M., and Sjoqvist, F. 1995a. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274:515-520.
33. Dahl M., Yue, Q., Roh, H., Johansson, I., Sawe, J., Sjoqvist, F., and Bertilsson, L. 1995b. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese, and Chinese subjects. Pharmacogenetics 5:159-164.
34. Dalen, P., Dahl, M., Ruiz, M., ResEng, J. N., and Bertilsson, L. 1998. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol.Ther. 63:444-452.
35. Dalen P., Dahl, M., Eichelbaum, M., Bertilsson, L., and Wilkinson, G. R. 1999. Disposition of debrisoquine in Caucasians with different CYP2D6 genotypes including those with multiple genes. Pharmacogenetics 9:697-706.
36. Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. M., Wolf, C. R., and Zanger, U. M. 1996. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
37. Daniels, J., Williams, J., Asherson, P., McGuffin, P., and Owen, M. 1995. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am. J. Med. Genet. 60:85-87.
38. Dayer, P., Desmeules, J., Leemann, T., and Striberni, R. 1988. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem. Biophys. Res. Commun. 152:411-416.
39. de Groot, M., Bijloo, G., van Acker,F., Fonseca-Guerra, C., Snijders, J., and Vermeulen, N. 1997. Extension of a predictive substrate model for human cytochrome P4502D6. Xenobiotica 27:357-368. (Pubitemid 27199381)
40. de la Torre, R., Farre, M., Ortuno, J., Mas, M., Brenneisen, R., Roset, P., Segura, J., and Cami, J. 2000. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol. 49:104-109.
41. den Dunnen, J. T., and Antonarakis, S. E. 2001. Nomenclature for the description of human sequence variations. Hum. Genet. 109:121-124.
42. Dong, H., Haining, R. L., Thummel, K. E., Rettie, A. E., and Nelson, S. D. 2000. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab. Dispos. 28:1397-4000.
43. Elbaz, A., Levecque, C., Clavel, J., Vidal, JS., Richard, F., Amouyel, P., Alperovitch, A., Chartier-Harlin, M. C., and Tzourio, C. 2004. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann. Neurol. 55:430-434.
44. Evans, W., and Relling, M. 1991. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ration to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1:143-148.
45. Evans, W. E., Relling, M. V., Rahman, A., McLeod, H. L., Scott, E. P., and Lin, J. 1993. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J. Clin. Invest. 91:2150-2154.
46. Febbo, P. G., Kantoff, P. W., Giovannucci, E., Brown, M., Chang, G., Hennekens, C. H., and Stampfer, M. 1998. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer epidemiology, biomarkers and prevention. Am. Assoc. Cancer 7:1075-1078.
47. Fleming, C., Kaisary, A., Wilkinson, G., Smith, P., and Branch, R. 1992. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics 2:128-134.
48. Gaedigk, A., Bhathena, A., Ndjountche, L., Pearce, R. E., Abdel-Rahman, S. M., Alander, S. W., Bradford, L, D., Rogan, P. K., and Leeder, J. S. 2005. Identification and characterization of novel sequence variations in the cytochrome P4502D6 gene in African-Americans. Pharmacogenom. J 5:173-182.
49. Gaedigk, A., Bradford, L. D., Alander, S. W., and Leeder, J. S. 2006. CYP2D6*36 gene arrangements within the CYP2D6 locus: Association of CYP2D6*36 with poor metabolizer status. Drug Metab. Dispos. 34:563-569.
50. Garcia-Barcelo, M., Chow, L. Y., Chiu, H. F., Wing, Y. K., Lee, D. T., Lam, K. L., and Waye, M. M. 2000. Genetic analysis of the CYP2D6 locus in Hong Kong Chinese population. Clin. Chem. 46:18-23. (Pubitemid 30090955)
51. Garte, S., Gaspari, L., Alexandrie, A., and Ambrosone, C. 2001. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10:1239-1248.
52. George, J., Byth, K., and Farrell, G. 1995. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem. Pharmacol. 50:727-730.
53. Gilham, D., Cairns, W., Paine, M., Modi, S., Poulsom, R., Roberts, G., and Wolf. C. 1997. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27:111-125.
54. Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., Desta, Z., Perez, E. A., and Ingle, J. N. 2005. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23:9312-9318.
55. Griese E., Zanger, U. M., Brudermanns, U., Gaedigk, A., Mikus, G., Morike, K., Stuven, T., and Eichelbaum, M. 1998. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26.
56. Harhangi, B., Oostra, B., Heutink, P., van Duijn, C., Hofman, A., and Breteler, M. 2001. CYP2D6 polymorphism in Parkinson's disease: The Rotterdam Study. Movement Disorders 16:290-293. (Pubitemid 36049976)
57. He, N., Daniel, H. I., Hajiloo, L., and Shockley, D. 1999. Dextromethorphan O-demethylation polymorphism in an African-American population. Eur. J. Clin. Pharmacol. 55:457-459.
58. Hecht, S. 1996. Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Crit. Rev. Toxicol. 26:163-181.
59. Hedenmalm, K., Lindh, J. D., Sawe, J., and Rane, A. 2004. Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene. Eur. J. Clin. Pharmacol. 60:369-372.
60. Herraiz, T., Guillen, H., Aran, V. J., Idle, J. R., and Gonzalez, F. J. 2006 Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicol. Appl. Pharmacol. 216:387-398.
61. Hetzel, M. R., Law, M., Keal, E. E., Sloan, T. P., Idle, J. R., and Smith, R. L. 1980. Is there a genetic component in bronchial carcinoma in smokers? Thorax 35:709.
62. Hiroi, T., Imaoka, S., and Funae, Y. 1998. Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249:838-843.
63. Hoffmannn, D., and Hoffmann, I. 1997. The changing cigarette, 1950-1995. J. Toxicol. Environ. Health 50:307-364.
64. Idle, J. R., Armstrong, M., Boddy, A. V., Boustead, C., Cholerton, S., Cooper, J., Daly, A. K., Ellis, J., Gregory, W., and Hadidi, H. 1992. The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 2:246-258.
65. Ikenaga, Y., Fukuda, T., Fukuda, K., Nishida, Y., Naohara, M., Maune, H., and Azuma, J. 2005. The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution. Drug Metab. Pharmacokinet. 20:113-116.
66. Ingelman-Sundberg, M. 2005. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom. J. 5:6-13.
67. Isaza, C. A., Henao, J., Lopez, A. M., and Cacabelos, R. 2000. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Columbian population. Methods Findings Exp. Clin. Pharmacol. 22:695-705.
68. Islam, S., Wolf, C., Lennard, M., and Sternberg, M. 1991. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxlation. Carcinogenesis 12:2211-2219.
69. Jacqz-Aigrain, E., and Cresteil, T. 1992. Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. Dev. Pharmacol. Ther. 18:161-168.
70. Johansson I., Yue, Q. Y., Dahl, M. L., Heim, M., Sawe, J., Bertilsson, L., Meyer, U. A., Sjoqvist, F., and Ingelman-Sundber, M. 1994. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46:452-459.
71. Jonsson, E., Dahl, M., Roh, H., Jerling, M., and Sedvall, G. 1998. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphism and schizophrenia. Psychiat. Genet. 8:25-28.
72. Joost, O., Taylor, C. A., Thomas, C. A., Cupples, L. A., Saint-Hilaire, M. H., Feldman, R. G., Baldwin, C. T., and Myers, R. H. 1999. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease. Movement Disorders 14:590-595.
73. Jorge, L., Eichelbaum, M., Griese, E., Inaba, T., and Arias, T. 1999. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 9:217-228.
74. Jurima-Romet, M., Foster, BC., Rode, A., Casley, W. L., Vloshinsky, P., Huang, H. S., and Geersten, S. 1997. CYP2D6-related oxidation polymorphism in a Canadian Inuit population. Can. J. Physiol. Pharmacol. 75:165-172.
75. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., and Meyer, U. A. 1990. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 265:17209-17214.
76. Kaisary, A., Smith, P., Jaczq, E., McAllister, C., Wilkinson, G., Ray, W., and Branch, R. 1987. Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 47:5488-5493.
77. Kato, S., Bowmann E. D., Harrington, A. M., Blomeke, B., and Shields, P. G. 1995. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. JNCI 87:902-907.
78. Kimiskidis, V. K., Niopas, I., Firinidis, P. D., Kanaze, F. I., Gabrieli, C., Kazis, D., and Papagiannopoulos, S. 2005, Frequency distribution of dextromethorphan O-demethylation in a Greek population. Int. J. Clin. Pharmacol. Ther. 43:150-153.
79. Kirchheiner J., Schmidt, H., Tzvetkov, M., Keulen, JT., Lotsch, J., Roots, I., and Brockmoller, J. 2006. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenom. J. 7:257-265.
80. Kubota T., Yamaura, Y., Ohkawa, N., Hara, H., and Chiba, K. 2000. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 50:31-34.
81. Law, M. R., Hetzel, M. R., and Idle, J. R. 1989. Debrisoquine metabolism and genetic predisopsition to lung cancer. Br. J. Cancer 59:686-687.
82. Leathart, J., London, S. J., Steward, A., Adams, J. D., Idle, J. R., and Daly, A. K. 1998. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529-541.
83. Lee, S., Jang, I., Shin, S., Lee, K., Yim, D., Kim, S., Oh, S., and Lee, S. 1994. CYP1A2 activity as a risk factor for bladder cancer. J. Korean Med. Sci. 9:482-489.
84. Lee, S. Y., Sohn, K. M., Ryu, J. Y., Yoon, Y. R., Shin, J. G., and Kim, J. W. 2006. Sequence-based CYP2D6 genotyping in the Korean population. Ther. Drug Monit. 28:382-387.
85. Le Marchand, L., Sivaraman, L., Pierce, L., Seifried, A., Lum, A., Wilkens, L. R., and Lau, A. 1998. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities tobacco carcinogens. Cancer Res. 58:4858-4863.
86. Lewis, D. F. V. 1996. Cytochomes P450: Structure, functions and mechanism. London: Taylor & Francis.
87. Li, H., Feng, L., Xu, Y., Yao, L., Quyang, T., Li, J., Want, T., Fan, Z., Lin, B., and Li, J. 2006. The association of CYP2D6*10 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women. Acta Oncol. 45:597-601.
88. London, S. J., Daly, A. K., Leathart, J. B. S., Navidi, W. C., Carpenter, C. C., and Idle, J. R. 1997. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 18:1203-1214.
89. Lyun, A. O., Lennari, M. S., Tucker, G. T., and Woods, H. F. 1986. Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin. Pharmacol. Ther. 40:387-399.
90. Mahgoub, A., Idle, JR., Dring, LG., Lancaster, R., and Smith, R. L. 1977. Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586.
91. Marandi, T., Dahl, M. L., Rago, L., Kiivet, R., and Sjoqvist, F. 1997. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. Eur. J. Clin. Pharmacol. 53:257-260.
92. Marinac, J. S., Foxworth, J. W., and Willsie, S. K. 1995. Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in health Black American adult subjects. Ther. Drug Monitor. 17:120-124.
93. Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J. M., Spire, C., Lafitte, J. J., Meyer, U. A., and Broly, F. 1997. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
94. Masimirembwa, C., Hasler, J., Bertilssons, L., Johansson, I., Ekberg, O., and Ingelman-Sundberg, M. 1996. Pheontype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur. J. Clin. Pharmacol. 51:117-122.
95. McFee, R., Mofenson, H., and Caraccio, T. 2000. Dextromethorphan: Another "Ecstasy"? Arch. Intern. Med. 9:123.
96. McLellan, R. A., Oscarson, M., Seidegard, J., Evans, D., and Ingelman-Sundberg, M. 1997. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7:187-191.
97. Messina, E. S., Tyndale, R. F., and Sellers, E. M. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282:1608-1614.
98. Miller, G. P., Hanna, I. H., Nishimura, Y., and Guengerich, F. P. 2001. Oxidation of phenethylamine derivatives by cytochrome P450 2D6: The issue of substrate protonation in binding and catalysts. Biochemistry 40:14215-14223.
99. Modi, S., Gilham, D., Sutcliffe, M., Lian, L., Primrose, W., Wolf, C., and Roberts, G. 1997. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 36:4461-4470.
100. Munoz, S., Vollrath, V., Vallejos, M., Miquel, J., Covarrubias, C., and Raddatz, A. 1998. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 8:343-351.
101. Naveen, A. T., Adithan, C., Soya, S. S., Gerard, N., and Krishnamoorthy, R. 2006. CYP2D6 genetic polymorphism in South Indian populations. Biol. Pharm. Bull. 29:1655-1658.
102. Nebert, D. W. 1991. Polymorphism of human CYP2D genes involved in drug metabolism possible relationship to individual cancer risk. Cancer Cell 3:93-96.
103. Nebert, D. W., McKinnon, R. A., and Puga, A. 1996. Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer. DNA Cell Biol. 15:273-280.
104. Nowak, M. P., Tyndale, R. F., and Sellers, E. M. 1997. CYP2D6 phenotype and genotype in a Canadian native Indian population. Pharmacogenetics 7:145-148.
105. Oscarson, M., Hidestrand, M., Johansson, I., and Ingelman-Sundberg, M. 1997. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol. 52:1034-1040.
106. Oscarson, M., Gullsten, H., Rautio, A., Bernal, ML., Sinues, B., Dahl, M., Stengård, J. H., Pelkonen, O., Raunio, H., Ingelman-Sundberg, M. 1998. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett. 438:201-205.
107. Patten, C., Smith, T., Murphy, S., Wang, M., Lee, J., Tynes, R., Koch, P., and Yang, C. 1996. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Arch. Biochem. Biophys. 333:127-138.
108. Payami, H., Lee, N., Zareparsi,S., Gonzales-McNeal, M., Camicioli, R., Bird, T., Sexton, G., Gancher, S., Kay, J., Calhoun, D., Swanson, P., and Nutt, J. 2001. Parkinson's disease, CYP2D6 polymorphism and age. Neurology 56:1363-1370.
109. Pedersen, R. S., Damkier, P., and Brosen, K. 2005. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: A population study. Clin. Pharmacol. Ther. 77:458-467.
110. Pianezza, M. L., Sellers, E. M., and Tyndale, R. F. 1998. Nicotine metabolism defect reduces smoking. Nature 393:750.
111. Raimundo, S., Toscano, C., Klein, K., Griese, E. U., Eichelbaum, M., Schwab, M., and Zanger, U. M. 2004. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 76:128-138.
112. Ramamoorthy, Y., Tyndale, R., and Sellers, E. 2001. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11:477-487.
113. Rasmussen, J. O., Christensen, M., Svendsen, J. M., Skausig, O., Hansen, E. L., and Nielsen, K. A. 2006. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand. J. Clin. Lab. Invest. 66:129-136.
114. Relling, M. V., Cherrie, J., Schell, M. J., Petros, W. P., Meyer, W. H., and Evans, W. E. 1991. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin. Pharmacol. Ther. 50:308-313.
115. Roh, H. K., Dahl, M., Johansson, I., Ingelman-Sundberg, M., Cha, Y., and Bertilsson, L. 1996. Debrisoquine and s-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6:441-447. (Pubitemid 26380100)
116. Romkes-Sparks, M., Mnuskin, A., Chern, H., Persad, R., Fleming, C., Sibley, G. N., Smith, P., Wilkinson, G. R., and Branch, R. A. 1994. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis 15:1955-1961.
117. Romkes, M., Chern, H., Lesnick, T., Becich, M., Persad, R., Smith, P., and Branch, R. 1996. Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer. Carcinogenesis 17:1057-1062.
118. Rostami-Hodjegan, A., Lennard, M. S., Woods, H. F., and Tucker, G. T. 1998. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 8:227-238.
119. Rumack, B. H., and Peterson R. G. 1978. Acetaminophen overdose: incidence, diagnosis and management in 416 patients. Pediatrics 62: 898-903.
120. Saarikoski, ST., Sata, F., Husgafvel-Pursiainen, K., Rautalahti, M., Haukka, J., Impivaara, O., Jarvisalo, J., Vainio, H., and Hirvonen, A. 2000. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behavior. Pharmacogenetics 10:5-10.
121. Sabbagh, N., Brice, A., Marez, D., Durr, A., Legrand, M., Lo-Guidice, J., Destee, A., Agid, Y., and Broly, F. 1999. CYP2D6 polymorphism and Parkinson's disease susceptibility. Movement Disorders 14:230-236.
122. Sachse C., Brockmoller, J., Bauer, S., and Roots, I. 1997. Cytochrome P4502D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60:284-295.
123. Sachse C., Brockmoller, J., Hildebrand, M., Muller, K., and Roots, I. 1998. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 8:181-185.
124. Sams, C., Mason, H. J., and Rawbone, R. 2000. Evidence for the activation or organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol. Lett. 116:217-221.
125. Segura, M., Farre, M., Pichini, S., Peiro, A. M., Roset, P. N., Ramirez, A., Ortuno, J., Pacifici, R., Zuccaro, P., Segura, J., and de la Torre, R. 2005. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: Use of paroxetine as a metabolic inhibitor probe. Clin. Pharmacokinet. 44:649-660.
126. Shams, M. E., Arneth, B., Hiemke, C., Dragicevic, A., Muller, M. J., Kaiser, R., Lackner, K., and Hartter, S. 2006. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J. Clin. Pharm. Ther. 31:493-502.
127. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol.Exp.Ther. 270:414-423.
128. Shows, T. B., McAlpine, P. J., Boucheix, C., Collins, F. S., Conneally, P. M., Frezal, J., Gershowitz, H., Goodfellow, P. N., Hall, J. G., Issitt, P., Jones, C. A., Knowles, B. B., Lewis, M., McKusick, V. A., Meisler, M., Morton, N. E., Rubenstein, P., Schanfield, M. S., Schmickel, R. D., Skolnick, M. H., Spence, M. A., Sutherland, G. R., Traver, M., Vancong, N., and Willard, H. F. 1987. Guidelines for human gene nomenclature. An international system for human gene nomenclature. Cytogenet. Cell Genet. 146:11-28.
129. Simooya, O., Njunju, E., and Hodjegan, A. R. 1993. Debrisoquin and metoprolol oxidation in Zambians: A population study. Pharmacogenetics 3:205-208.
130. Smith, D. A., Abel, S. M., Hyland, R., and Jones, B. C. 1998. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 28:1095-1128.
131. Sommers, D. K., Monerieff, J., and Avenant, J. 1988. Polymorphism of the 4-hydroxylation of debrisoquin in the San Bushmen of Southern Africa. Hum. Toxicol. 7:273-276.
132. Sosa-Macias, M., Elizondo, G., Flores-Perez, C., Flores-Perez, J., Bradley-Alvarez, F., Alanos-Banuelos, R. E., and Lares-Asseff, I. 2006. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J. Clin. Pharmacol. 46:527-536.
133. Soyama, A., Saito, Y., Miyajima, A., Ohno, Y., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ozawa, S., and Sawada, J. 2006. Sequence-based analysis of the CYP2D6*36-CYP2D6*10 tandem-type arrangement, a major CYP2D6*10 haplotype in the Japanese population. Drug Metab. Pharmacokinet. 21:208-216.
134. Stefanovic, M., Topic, E., Ivanisevic, A., Relja, M., and Korsic, M. 2000. Genotyping of CYP2D6 in Parkinson's disease. Clin. Chem. Lab. Med. 38:929-934.
135. Tanaka, E. 1998. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J. Clin. Pharm. Ther. 23:247-255.
136. Taningher, M., Malacarne, D., Izzotti, A., Ugolini, D., and Parodi, S. 1999. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat. Res. 436:227-261.
137. Tateishi T., Chida, M., Ariyoshi, N., Mizorogi, Y., Kamataki, T., and Kobayashi, S. 1999. Analysis of the CYP2D6 gene in relation to destromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther. 65:570-575.
138. Thuerauf, N., and Lunkenheimer, J. 2006. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur. Arch. Psychiat. Clin. Neurosci. 256:287-293.
139. Toscano, C., Klein, K., Blievernicht, J., Schaeffeler, E., Saussele, T., Raimundo, S., Eichelbaum, M., Schwab, M., and Zanger, UM. 2006a. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: Evidence for modulation of splicing events. Pharmacogenet. Genom. 16:755-766.
140. Toscano, C., Raimundo, S., Klein, K., Eichelbaum, M., Schwab, M., and Zanger, U. M. 2006b. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenet. Genom. 16:767-770.
141. Vandel, P., Haffen, E., Vandel, S., Bonin, B., Nezelof, S., Sechter, D., Broly, F., Bizouard, P., and Dalery, J. 1999. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur. J. Clin. Pharmacol. 55:659-665.
142. Vincent-Viry, M., Fournier, B., and Galteau, M. M. 2000. The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab. Dispos. 28:617-619.
143. Wadelius, M., Autrup, J., Stubbins, M., Andersson, S., Johansson, J., Wadelius, C., Wolf, C., Autrup, H., and Rane, A. 1999. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 9:333-340.
144. Wang, S. L., Huang, J. D., Lai, M. D., Liu, B. H., and Lai, M. L. 1993. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP an DNA sequence of CYP2D6. Clin. Pharmacol. Ther. 53:410-418.
145. Wang S., Lai, M., and Huang, J. 1999. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab. Dispos. 27:385-388.
146. Wang, G., Zhang, H., He, F., Fang, X., Wang, S., Lai, M., and Huang, J. 2006. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur. J. Clin. Pharmacol. 62:927-931.
147. Woolhouse, N. M., Andoh, B., and Mahgoub, A. 1979. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin. Pharmacol. Ther. 26:584-591.
148. Woolhouse, N. M., Eichelbaum, M., and Oates, N. S. 1985. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin. Pharmacol. Ther. 37:512-527.
149. Woolverton, W. L., and Johnson, K. M. 1992. Neurobiology of cocaine abuse. Trends Pharmacol Sci. 13:193-200.
150. Yamada, H., Dahl, M., Lannfelt, L., Viitanen, M., Winblad, B., and Sjoqvist, F. 1998. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur. J. Clin. Pharmacol. 54:479-481. (Pubitemid 28418816)
151. Yamazaki, H., Inui, Y., Yun, C., Guengerich, F. and Shimada, T. 1992. Cytrochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13:1789-1794.
152. Yamazaki, H., Kiyotani, K., Tsubuko, S., Matsunaga, M., Miura, J., Kobayashi, S., Kamataki, T., Fujieda, M., and Saito, T. 2003. Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab. Pharmacokinet. 18:269-271.
153. Yang, C. S., and Smith, T. J. 1996. Mechanisms of nitrosamine bioactivation and carcinogenesis. Adv. Exp. Med. Biol. 387:385-394.
154. Yokoi T., Kosaka, Y., Chida, M., Chiba, K., Nakamura, H., Ishizaki, T., Kinoshita, M., Sato, K., Gonzalez, F., and Kamataki, T. 1996. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 6:395-401.
155. Yue Q., Zhong, Z., Tybring, G., Dalen, P., Dahl, M., Bertilsson, L., and Sjoqvist, F. 1998. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 64:384-390.
156. Zanger, U. M., Raimundo, S., and Eichelbaum, M. 2004. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmakol. 369:23-37.